Sotabase

Career

· Software Engineer, Amazon Web Services (AWS)2020–

Publications (70)

Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-κ B-like nuclear protein
Journal of Neuroimmunology · 1992
160
cited
c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations*
Journal of Biological Chemistry · 2008
137
cited
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
Journal of Medicinal Chemistry · 2008
131
cited
STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Cancer Research · 2011
119
cited
Enhanced PAPSS2/VCAN sulfation axis is essential for Snail-mediated breast cancer cell migration and metastasis
Cell Death and Differentiation · 2018
102
cited
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
Journal of Medicinal Chemistry · 2008
90
cited
Design, synthesis, and biological evaluation of potent c-Met inhibitors.
Journal of Medicinal Chemistry · 2008
82
cited
hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · 2015
80
cited
GeCo: Quality Counterfactual Explanations in Real Time
Proceedings of the VLDB Endowment · 2021
74
cited
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Journal of Medicinal Chemistry · 2012
69
cited
An Update on the Structure of hERG
Frontiers in Pharmacology · 2020
65
cited
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide
Journal of Molecular and Cellular Cardiology · 2015
56
cited
Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Cancer Research · 2008
55
cited
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.
Bioorganic & Medicinal Chemistry Letters · 2009
51
cited
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Molecular Cancer Therapeutics · 2016
51
cited
Ranolazine inhibition of hERG potassium channels: Drug–pore interactions and reduced potency against inactivation mutants
Journal of Molecular and Cellular Cardiology · 2014
46
cited
Better Together: Unifying Datalog and Equality Saturation
Proceedings of the ACM on Programming Languages · 2023
45
cited
Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking
Biochemical Pharmacology · 2016
45
cited
A Nondesensitizing Kainate Receptor Point Mutant
Molecular Pharmacology · 2009
36
cited
Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker
Journal of Biological Chemistry · 2018
36
cited
Sotabase
Yihong Zhang | Researcher Profile | Sotabase | Sotabase